According to Persistence Market Research, the global autogenous vaccines market is bound to witness a CAGR of 5.5% between 2021 and 2031.
Autogenous vaccines work better with the living organisms as they do deal with mass produced immunologically charged material, which might be an outcome of immune response preventing the damage of the tissues of organism. As such, as prevention takes over cure, the market for autogenous vaccines is bound to stand in a good stead in the upcoming period. Plus, these vaccines are environmentally-friendly, leaving no residue while the vaccine is being developed.
Autogenous Vaccines Market Dispersion
Autogenous Vaccines market, by strain, spans viral strain and bacterial strain. By end-user, it’s veterinary clinics and hospitals, veterinary research institutes, and livestock farming companies. Out of these, veterinary clinics and hospitals hold the largest market share, followed by livestock farming companies.
Europe holds the largest market share due to autogenous vaccines extensively used in countries such as Czech Republic, Slovak Republic, and Hungary North America follows suit due to the US being at the forefront herein. The USDA Animal Vaccine and Plant Health Inspection Service (APPHIS) and the USDA Animal Research Service (ARS) are conducting the surveillance program with the objective of encouraging animal health industry and researchers to upgrade the diagnostic reagents, and customized diagnostic assays for influenza. The Asia-Pacific is expected to grow at the fastest rate in the autogenous vaccines market in the next decade with growing awareness regarding animal health.
The Competitive Landscape states….is expected to grow at the fastest
The key participants in the autogenous vaccines market include Newport Laboratories, Inc., Phibro Animal Health, Elanco Animal Health, Ceva Sante Animale, ACE Laboratory Services, Huvepharma, Inc., AniCon Labor GmbH, Cambridge Technologies,, Dyntec s.r.o, Hygieia Biological Laboratories, HIPRA, Vaxxinova, Addison Biological Laboratory, Zoetis, Barramundi Asia Pte Ltd., and Kennebec River Biosciences.
Coming to developments, Ceva and ProBioGen inked a license agreement in October 2019 for producing vectorised poultry vaccines by making use of the latter’s proprietary AGE1.CR technology. Also, Apiam, in March 2018, completed acquisition of Passionate Vetcare for rendering services in Central Victorian region. Additionally, Vaxxinova, in February 2018, did acquire 100% shares of Epitopix. It’s an animal health company based in the US.
The Progressive Way
The fact that autogenous vaccines have been approved for usage by governments all over the world is bound to take the autogenous vaccines market to a new “high” in the forecast period.
Global Market Study on Autogenous Vaccines: Demand Surging from Livestock Farming Companies and Veterinary Research InstitutesRequest Sample